[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06353191":3,"trial-entities:NCT06353191":127,"trial-summary:NCT06353191":23},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":25,"interventions":28,"primary_outcomes":34,"secondary_outcomes":39,"sex":40,"minimum_age":41,"maximum_age":23,"healthy_volunteers":15,"eligibility_criteria":42,"std_ages":54,"locations":57,"central_contacts":118,"overall_officials":120,"references":122,"see_also_links":123},"NCT06353191","19-002566","Biomarkers to Predict Cancer Therapy-related Cardiotoxicity","Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity","RECRUITING","2031-12-31","2026-08","2026-08-18","2019-05-03","Mayo Clinic","OTHER",false,"This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.","PRIMARY OBJECTIVE:\n\nI. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT.\n\nOUTLINE: This is an observational study.\n\nPatients undergo blood sample collection and have their medical records reviewed on study. Patients may also optionally undergo ECG on study.",[19,20],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm",[],"OBSERVATIONAL",null,[],{"count":26,"type":27},693,"ESTIMATED",[29],{"type":14,"name":30,"description":31,"armGroupLabels":32},"Non-Interventional Study","Non-interventional study",[33],"Observational",[35],{"measure":36,"description":37,"timeFrame":38},"Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT","Assessed by the number of participants who participate and consent to have their specimen (blood draw) retained for future research.","Baseline",[],"ALL","18 Years",{"inclusion":43,"exclusion":52,"raw_text":53},[44,45,46,47,48,49,50,51],"18 years of age or older","Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy","One of the following:","Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment","Completed chemotherapy with no cardiotoxicity at least two years post treatment","Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity","An understanding of the protocol and its requirements, risks, and discomforts","The ability and willingness to sign an informed consent",[],"Inclusion Criteria:\n\n* 18 years of age or older\n* Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy\n* One of the following:\n\n  * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment\n  * Completed chemotherapy with no cardiotoxicity at least two years post treatment\n  * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity\n* An understanding of the protocol and its requirements, risks, and discomforts\n* The ability and willingness to sign an informed consent\n\nExclusion Criteria:\n\n\\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol",[55,56],"ADULT","OLDER_ADULT",[58,80,96,109],{"facility":59,"status":8,"city":60,"state":61,"zip":62,"country":63,"contacts":64,"geoPoint":77},"Mayo Clinic in Arizona","Scottsdale","Arizona","85259","United States",[65,70,74],{"name":66,"role":67,"phone":68,"email":69},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":71,"role":67,"phone":72,"email":73},"Myrah Manuel","480-574-3157","Manuel.Myrah@mayo.edu",{"name":75,"role":76},"Lida A. Mina, MD","PRINCIPAL_INVESTIGATOR",{"lat":78,"lon":79},33.50921,-111.89903,{"facility":81,"status":8,"city":82,"state":83,"zip":84,"country":63,"contacts":85,"geoPoint":93},"Mayo Clinic in Florida","Jacksonville","Florida","32224-9980",[86,87,91],{"name":66,"role":67,"phone":68,"email":69},{"name":88,"role":67,"phone":89,"email":90},"Pamela Williamson","904-953-4694","Williamson.Pamela@mayo.edu",{"name":92,"role":76},"Nadine Norton, PhD",{"lat":94,"lon":95},30.33218,-81.65565,{"facility":97,"status":8,"city":98,"state":83,"zip":99,"country":63,"contacts":100,"geoPoint":106},"Moffitt Cancer Center","Tampa","33612",[101,105],{"name":102,"role":67,"phone":103,"email":104},"Aixa Soyano, MD","813-745-8268","aixa.soyano@Moffitt.org",{"name":102,"role":76},{"lat":107,"lon":108},27.94752,-82.45843,{"facility":110,"status":111,"city":112,"state":113,"zip":114,"country":63,"geoPoint":115},"Mayo Clinic in Rochester","SUSPENDED","Rochester","Minnesota","55905",{"lat":116,"lon":117},44.02163,-92.4699,[119],{"name":66,"role":67,"phone":68,"email":69},[121],{"name":92,"affiliation":13,"role":76},[],[124],{"label":125,"url":126},"Mayo Clinic Clinical Trials","https:\u002F\u002Fwww.mayo.edu\u002Fresearch\u002Fclinical-trials",{"nct_id":4,"conditions":128,"biomarkers":131},[129,130],"Hematologic Neoplasm","Solid Neoplasm",[]]